{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T16:14:38Z","timestamp":1783440878668,"version":"3.54.6"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Protein J"],"DOI":"10.1007\/s10930-026-10333-9","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T09:15:27Z","timestamp":1779268527000},"page":"461-478","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting oral squamous cell carcinoma with venom peptides: mechanisms, selectivity and translational potential"],"prefix":"10.1007","volume":"45","author":[{"given":"Vanitha","family":"Marunganathan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imran","family":"Uddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"10333_CR1","doi-asserted-by":"publisher","first-page":"e15911","DOI":"10.7717\/peerj.15911","volume":"11","author":"N Rahadiani","year":"2023","unstructured":"Rahadiani N, Habiburrahman M, Stephanie M et al (2023) Estimated projection of oral squamous cell carcinoma annual incidence from twenty years registry data: a retrospective cross-sectional study in Indonesia. PeerJ 11:e15911. https:\/\/doi.org\/10.7717\/peerj.15911","journal-title":"PeerJ"},{"key":"10333_CR2","doi-asserted-by":"publisher","first-page":"1505833","DOI":"10.3389\/froh.2024.1505833","volume":"5","author":"RD Coletta","year":"2024","unstructured":"Coletta RD, Yeudall WA, Salo T (2024) Current trends on prevalence, risk factors and prevention of oral cancer. Front Oral Heal 5:1505833. https:\/\/doi.org\/10.3389\/froh.2024.1505833","journal-title":"Front Oral Heal"},{"key":"10333_CR3","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41368-023-00249-w","volume":"15","author":"Y Tan","year":"2023","unstructured":"Tan Y, Wang Z, Xu M et al (2023) Oral squamous cell carcinomas: state of the field and emerging directions. Int J Oral Sci 15:44. https:\/\/doi.org\/10.1038\/s41368-023-00249-w","journal-title":"Int J Oral Sci"},{"key":"10333_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/cre2.70092","author":"N Saghravanian","year":"2025","unstructured":"Saghravanian N, Tajdini Y, Saeedi P, Ghorbani M (2025) Assessing the 53-year epidemiological trends of oral squamous cell carcinoma (OSCC) in northeastern Iran. Clin Exp Dent Res. https:\/\/doi.org\/10.1002\/cre2.70092","journal-title":"Clin Exp Dent Res"},{"key":"10333_CR5","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.82552","author":"M D","year":"2025","unstructured":"D M, Thanikachalam, R, N C et al (2025) The demographic and clinical characteristics of oral squamous cell carcinoma: an institutional epidemiological study. Cureus. https:\/\/doi.org\/10.7759\/cureus.82552","journal-title":"Cureus"},{"key":"10333_CR6","doi-asserted-by":"publisher","first-page":"104235","DOI":"10.1016\/j.amjoto.2024.104235","volume":"45","author":"GP Sexton","year":"2024","unstructured":"Sexton GP, Hintze JM, Walsh P et al (2024) Epidemiology and management of oral cavity squamous cell carcinoma in Ireland. Am J Otolaryngol 45:104235. https:\/\/doi.org\/10.1016\/j.amjoto.2024.104235","journal-title":"Am J Otolaryngol"},{"key":"10333_CR7","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.3762\/bjoc.14.144","volume":"14","author":"MDT Torres","year":"2018","unstructured":"Torres MDT, Andrade GP, Sato RH et al (2018) Natural and redesigned wasp venom peptides with selective antitumoral activity. Beilstein J Org Chem 14:1693\u20131703. https:\/\/doi.org\/10.3762\/bjoc.14.144","journal-title":"Beilstein J Org Chem"},{"key":"10333_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpt.2025.03.005","author":"SK Ghodeif","year":"2025","unstructured":"Ghodeif SK, El-Fahla NA, Abdel-Rahman MA, El-Shenawy NS (2025) Arthropod venom peptides: pioneering nanotechnology in cancer treatment and drug delivery. Cancer Pathog Ther. https:\/\/doi.org\/10.1016\/j.cpt.2025.03.005","journal-title":"Cancer Pathog Ther"},{"key":"10333_CR9","doi-asserted-by":"publisher","first-page":"116015","DOI":"10.1016\/j.biopha.2023.116015","volume":"170","author":"JL D\u00edaz-G\u00f3mez","year":"2024","unstructured":"D\u00edaz-G\u00f3mez JL, Mart\u00edn-Estal I, Rivera-Aboytes E et al (2024) Biomedical applications of synthetic peptides derived from venom of animal origin: a systematic review. Biomed Pharmacother 170:116015. https:\/\/doi.org\/10.1016\/j.biopha.2023.116015","journal-title":"Biomed Pharmacother"},{"key":"10333_CR10","doi-asserted-by":"publisher","first-page":"100908","DOI":"10.18632\/oncotarget.21740","volume":"8","author":"R Ma","year":"2017","unstructured":"Ma R, Mahadevappa R, Kwok HF (2017) Venom-based peptide therapy: insights into anti-cancer mechanism. Oncotarget 8:100908\u2013100930. https:\/\/doi.org\/10.18632\/oncotarget.21740","journal-title":"Oncotarget"},{"key":"10333_CR11","doi-asserted-by":"publisher","first-page":"15437","DOI":"10.3390\/ijms232315437","volume":"23","author":"L Ageitos","year":"2022","unstructured":"Ageitos L, Torres MDT, de la Fuente-Nunez C (2022) Biologically active peptides from venoms: applications in antibiotic resistance, cancer, and beyond. Int J Mol Sci 23:15437. https:\/\/doi.org\/10.3390\/ijms232315437","journal-title":"Int J Mol Sci"},{"key":"10333_CR12","doi-asserted-by":"publisher","first-page":"587","DOI":"10.3390\/md17100587","volume":"17","author":"P Anand","year":"2019","unstructured":"Anand P, Filipenko P, Huaman J et al (2019) Selective Inhibition of Liver Cancer Cells Using Venom Peptide. Mar Drugs 17:587. https:\/\/doi.org\/10.3390\/md17100587","journal-title":"Mar Drugs"},{"key":"10333_CR13","doi-asserted-by":"publisher","first-page":"1465459","DOI":"10.3389\/fchem.2024.1465459","volume":"12","author":"L Freuville","year":"2024","unstructured":"Freuville L, Matthys C, Quinton L, Gillet J-P (2024) Venom-derived peptides for breaking through the glass ceiling of drug development. Front Chem 12:1465459. https:\/\/doi.org\/10.3389\/fchem.2024.1465459","journal-title":"Front Chem"},{"key":"10333_CR14","doi-asserted-by":"publisher","first-page":"105327","DOI":"10.1016\/j.phrs.2020.105327","volume":"164","author":"S Mirzaei","year":"2021","unstructured":"Mirzaei S, Fekri HS, Hashemi F et al (2021) Venom peptides in cancer therapy: an updated review on cellular and molecular aspects. Pharmacol Res 164:105327. https:\/\/doi.org\/10.1016\/j.phrs.2020.105327","journal-title":"Pharmacol Res"},{"key":"10333_CR15","doi-asserted-by":"publisher","first-page":"165","DOI":"10.4103\/RPS.RPS_75_24","volume":"20","author":"R Ghavimi","year":"2025","unstructured":"Ghavimi R, Mahmoudi S, Mohammadi M et al (2025) Exploring the potential of anticancer peptides as therapeutic agents for cancer treatment. Res Pharm Sci 20:165\u2013187. https:\/\/doi.org\/10.4103\/RPS.RPS_75_24","journal-title":"Res Pharm Sci"},{"key":"10333_CR16","doi-asserted-by":"publisher","first-page":"6964","DOI":"10.3390\/ijms25136964","volume":"25","author":"A Caruntu","year":"2024","unstructured":"Caruntu A, Yang S-F, Acero J (2024) New insights for an advanced understanding of the molecular mechanisms in oral squamous cell carcinoma. Int J Mol Sci 25:6964. https:\/\/doi.org\/10.3390\/ijms25136964","journal-title":"Int J Mol Sci"},{"key":"10333_CR17","doi-asserted-by":"publisher","first-page":"107769","DOI":"10.1016\/j.biotechadv.2021.107769","volume":"50","author":"J Giribaldi","year":"2021","unstructured":"Giribaldi J, Smith JJ, Schroeder CI (2021) Recent developments in animal venom peptide nanotherapeutics with improved selectivity for cancer cells. Biotechnol Adv 50:107769. https:\/\/doi.org\/10.1016\/j.biotechadv.2021.107769","journal-title":"Biotechnol Adv"},{"key":"10333_CR18","doi-asserted-by":"publisher","first-page":"621","DOI":"10.3390\/biom15050621","volume":"15","author":"LG Cabral","year":"2025","unstructured":"Cabral LG, de Martins S, de Paulo IM A, et al (2025) Molecular mechanisms in the carcinogenesis of oral squamous cell carcinoma: a literature review. Biomolecules 15:621. https:\/\/doi.org\/10.3390\/biom15050621","journal-title":"Biomolecules"},{"key":"10333_CR19","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/jop.13296","volume":"51","author":"GG Pereira","year":"2022","unstructured":"Pereira GG, Pontes FSC, Soares CD et al (2022) Oral and maxillofacial manifestations of IgG4-related disease: a clinicopathological study. J Oral Pathol Med 51:493\u2013500. https:\/\/doi.org\/10.1111\/jop.13296","journal-title":"J Oral Pathol Med"},{"key":"10333_CR20","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS20-PS1-01","author":"N Masuda","year":"2021","unstructured":"Masuda N, Ohsumi S, Nishimura R et al (2021) Abstract PS1-01: combined analysis of the WORTH 1 and WORTH 2 studies of ipsilateral breast tumor recurrence after breast conservative surgery without radiotherapyusing the 5-mm thick slice and 5-mm free margin method. Cancer Res. https:\/\/doi.org\/10.1158\/1538-7445.SABCS20-PS1-01","journal-title":"Cancer Res"},{"key":"10333_CR21","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/ijms26010002","volume":"26","author":"LM Moreno-Vargas","year":"2024","unstructured":"Moreno-Vargas LM, Prada-Gracia D (2024) Cancer-targeting applications of cell-penetrating peptides. Int J Mol Sci 26:2. https:\/\/doi.org\/10.3390\/ijms26010002","journal-title":"Int J Mol Sci"},{"key":"10333_CR22","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.crtox.2021.09.001","volume":"2","author":"VV Achar","year":"2021","unstructured":"Achar VV, M U H RR et al (2021) Venom peptides: a comprehensive translational perspective in pain management. Curr Res Toxicol 2:329\u2013340. https:\/\/doi.org\/10.1016\/j.crtox.2021.09.001","journal-title":"Curr Res Toxicol"},{"key":"10333_CR23","doi-asserted-by":"publisher","first-page":"11686","DOI":"10.3390\/ijms252111686","volume":"25","author":"K Wang","year":"2024","unstructured":"Wang K, Tao L, Zhu M et al (2024) Melittin inhibits colorectal cancer growth and metastasis by ac-tivating the mitochondrial apoptotic pathway and suppressing epithelial\u2013mesenchymal transition and angiogenesis. Int J Mol Sci 25:11686. https:\/\/doi.org\/10.3390\/ijms252111686","journal-title":"Int J Mol Sci"},{"key":"10333_CR24","doi-asserted-by":"publisher","first-page":"2284517","DOI":"10.1080\/13510002.2023.2284517","volume":"28","author":"X Li","year":"2023","unstructured":"Li X, Li Z, Meng Y-Q et al (2023) Melittin kills A549 cells by targeting mitochondria and blocking mitophagy flux. Redox Rep 28:2284517. https:\/\/doi.org\/10.1080\/13510002.2023.2284517","journal-title":"Redox Rep"},{"key":"10333_CR25","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.biopha.2016.10.041","volume":"84","author":"S Satitmanwiwat","year":"2016","unstructured":"Satitmanwiwat S, Changsangfa C, Khanuengthong A et al (2016) The scorpion venom peptide BmKn2 induces apoptosis in cancerous but not in normal human oral cells. Biomed Pharmacother 84:1042\u20131050. https:\/\/doi.org\/10.1016\/j.biopha.2016.10.041","journal-title":"Biomed Pharmacother"},{"key":"10333_CR26","doi-asserted-by":"publisher","first-page":"555945","DOI":"10.19080\/CTBEB.2018.16.555945","volume":"16","author":"R Kant Upadhyay","year":"2018","unstructured":"Kant Upadhyay R (2018) Use of animal venom peptides\/toxins in cancer therapeutics. Curr Trends Biomed Eng Biosci 16:555945. https:\/\/doi.org\/10.19080\/CTBEB.2018.16.555945","journal-title":"Curr Trends Biomed Eng Biosci"},{"key":"10333_CR27","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.toxicon.2013.07.012","volume":"76","author":"V Quintero-Hern\u00e1ndez","year":"2013","unstructured":"Quintero-Hern\u00e1ndez V, Jim\u00e9nez-Vargas JM, Gurrola GB et al (2013) Scorpion venom components that affect ion-channels function. Toxicon 76:328\u2013342. https:\/\/doi.org\/10.1016\/j.toxicon.2013.07.012","journal-title":"Toxicon"},{"key":"10333_CR28","doi-asserted-by":"publisher","first-page":"4533","DOI":"10.3390\/molecules29194533","volume":"29","author":"LG Cabral","year":"2024","unstructured":"Cabral LG, de Oliveira S, Oliveira CS VX, et al (2024) Antitumoral and antiproliferative potential of synthetic derivatives of scorpion peptide IsCT1 in an oral cavity squamous carcinoma model. Molecules 29:4533. https:\/\/doi.org\/10.3390\/molecules29194533","journal-title":"Molecules"},{"key":"10333_CR29","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3390\/toxins17030114","volume":"17","author":"K Xin","year":"2025","unstructured":"Xin K, Sun R, Xiao W et al (2025) Short peptides from asian scorpions: bioactive molecules with promising therapeutic potential. Toxins (Basel) 17:114. https:\/\/doi.org\/10.3390\/toxins17030114","journal-title":"Toxins (Basel)"},{"key":"10333_CR30","doi-asserted-by":"publisher","first-page":"e0215391","DOI":"10.1371\/journal.pone.0215391","volume":"14","author":"M Okada","year":"2019","unstructured":"Okada M, Ortiz E, Corzo G, Possani LD (2019) Pore-forming spider venom peptides show cytotoxicity to hyperpolarized cancer cells expressing K+ channels: a lentiviral vector approach. PLoS ONE 14:e0215391. https:\/\/doi.org\/10.1371\/journal.pone.0215391","journal-title":"PLoS ONE"},{"key":"10333_CR31","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.3390\/molecules30122594","volume":"30","author":"LG Cabral","year":"2025","unstructured":"Cabral LG, de Oliveira S, Oliveira CS VX, et al (2025) Evaluation of the antitumor and antiproliferative potential of synthetic peptides derived from IsCT1, associated with cisplatin, in squamous cell carcinoma of the oral cavity. Molecules 30:2594. https:\/\/doi.org\/10.3390\/molecules30122594","journal-title":"Molecules"},{"key":"10333_CR32","doi-asserted-by":"publisher","first-page":"991","DOI":"10.3390\/ph5090991","volume":"5","author":"J Regberg","year":"2012","unstructured":"Regberg J, Srimanee A, Langel \u00dc (2012) Applications of cell-penetrating peptides for tumor targeting and future cancer therapies. Pharmaceuticals 5:991\u20131007. https:\/\/doi.org\/10.3390\/ph5090991","journal-title":"Pharmaceuticals"},{"key":"10333_CR33","doi-asserted-by":"publisher","first-page":"692","DOI":"10.3390\/molecules23030692","volume":"23","author":"M Moga","year":"2018","unstructured":"Moga M, Dimienescu O, Arv\u0103tescu C et al (2018) Anticancer activity of toxins from bee and snake venom: an overview on ovarian cancer. Molecules 23:692. https:\/\/doi.org\/10.3390\/molecules23030692","journal-title":"Molecules"},{"key":"10333_CR34","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41419-023-05929-3","volume":"14","author":"D Li","year":"2023","unstructured":"Li D, Peng X, He G et al (2023) Crosstalk between autophagy and CSCs: molecular mechanisms and translational implications. Cell Death Dis 14:409. https:\/\/doi.org\/10.1038\/s41419-023-05929-3","journal-title":"Cell Death Dis"},{"key":"10333_CR35","doi-asserted-by":"publisher","first-page":"4341","DOI":"10.21037\/tcr-24-182","volume":"13","author":"T Tao","year":"2024","unstructured":"Tao T, Zhang F, Chai L et al (2024) Effect of Agkistrodon acutus venom (AAVC-I) on apoptosis through modulation of the Keap1\/Nrf2 pathway in HSC-3 oral squamous cell carcinoma cells. Transl Cancer Res 13:4341\u20134353. https:\/\/doi.org\/10.21037\/tcr-24-182","journal-title":"Transl Cancer Res"},{"key":"10333_CR36","doi-asserted-by":"publisher","first-page":"174022","DOI":"10.1016\/j.ejphar.2021.174022","volume":"899","author":"B Akhtar","year":"2021","unstructured":"Akhtar B, Muhammad F, Sharif A, Anwar MI (2021) Mechanistic insights of snake venom disintegrins in cancer treatment. Eur J Pharmacol 899:174022. https:\/\/doi.org\/10.1016\/j.ejphar.2021.174022","journal-title":"Eur J Pharmacol"},{"key":"10333_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14786419.2024.2423042","volume":"40","author":"K Kandaswamy","year":"2024","unstructured":"Kandaswamy K, Guru A (2024) How peptides from venomous and poisonous animals can be used to treat oral cancer: possible mechanisms of action. Nat Prod Res 40:1\u20132. https:\/\/doi.org\/10.1080\/14786419.2024.2423042","journal-title":"Nat Prod Res"},{"key":"10333_CR38","doi-asserted-by":"publisher","first-page":"559","DOI":"10.4103\/1735-5362.327503","volume":"16","author":"A Shoari","year":"2021","unstructured":"Shoari A, Khodabakhsh F, Ahangari Cohan R et al (2021) Anti-angiogenic peptides application in cancer therapy: a review. Res Pharm Sci 16:559\u2013574. https:\/\/doi.org\/10.4103\/1735-5362.327503","journal-title":"Res Pharm Sci"},{"key":"10333_CR39","doi-asserted-by":"publisher","first-page":"965882","DOI":"10.3389\/fonc.2022.965882","volume":"12","author":"B Majc","year":"2022","unstructured":"Majc B, Novak M, Lah TT, Kri\u017eaj I (2022) Bioactive peptides from venoms against glioma progression. Front Oncol 12:965882. https:\/\/doi.org\/10.3389\/fonc.2022.965882","journal-title":"Front Oncol"},{"key":"10333_CR40","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.3390\/cells12071023","volume":"12","author":"FC de Mato","year":"2023","unstructured":"de Mato FC, Barreto N, Cordeiro G et al (2023) Isolated peptide from spider venom modulates dendritic cells in vitro: a possible application in oncoimmunotherapy for glioblastoma. Cells 12:1023. https:\/\/doi.org\/10.3390\/cells12071023","journal-title":"Cells"},{"key":"10333_CR41","doi-asserted-by":"crossref","unstructured":"Sarode G, Ghone U, Sarode S et al (2023) Phospholipase A2 in oral cancer. Phospholipases in physiology and pathology. Elsevier, pp 145\u2013156","DOI":"10.1016\/B978-0-323-95697-0.00018-2"},{"key":"10333_CR42","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1002\/cre2.590","volume":"8","author":"R Nocini","year":"2022","unstructured":"Nocini R, Vianini M, Girolami I et al (2022) PD-L1 in oral squamous cell carcinoma: a key biomarker from the laboratory to the bedside. Clin Exp Dent Res 8:690\u2013698. https:\/\/doi.org\/10.1002\/cre2.590","journal-title":"Clin Exp Dent Res"},{"key":"10333_CR43","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.semcancer.2022.12.003","volume":"88","author":"M Oladejo","year":"2023","unstructured":"Oladejo M, Paulishak W, Wood L (2023) Synergistic potential of immune checkpoint inhibitors and therapeutic cancer vaccines. Semin Cancer Biol 88:81\u201395. https:\/\/doi.org\/10.1016\/j.semcancer.2022.12.003","journal-title":"Semin Cancer Biol"},{"key":"10333_CR44","doi-asserted-by":"publisher","first-page":"213903","DOI":"10.1016\/j.bioadv.2024.213903","volume":"162","author":"PS Chary","year":"2024","unstructured":"Chary PS, Shaikh S, Rajana N et al (2024) Unlocking nature\u2019s arsenal: nanotechnology for targeted delivery of venom toxins in cancer therapy. Biomater Adv 162:213903. https:\/\/doi.org\/10.1016\/j.bioadv.2024.213903","journal-title":"Biomater Adv"},{"key":"10333_CR45","doi-asserted-by":"publisher","first-page":"532","DOI":"10.2174\/1389203716666150515125002","volume":"16","author":"W Jay","year":"2015","unstructured":"J\u00e9ssica Kele Arruda Mac\u00eado, Jay W, Fox 1 M de SC (2015) Disintegrins from snake venoms and their applications in cancer research and therapy. Curr Protein Pept Sci 16:532\u2013548. https:\/\/doi.org\/10.2174\/1389203716666150515125002","journal-title":"Curr Protein Pept Sci Volume"},{"key":"10333_CR46","doi-asserted-by":"publisher","first-page":"107430","DOI":"10.1016\/j.phrs.2024.107430","volume":"209","author":"LF Laurindo","year":"2024","unstructured":"Laurindo LF, de Lima EP, Laurindo LF et al (2024) The therapeutic potential of bee venom-derived Apamin and Melittin conjugates in cancer treatment: a systematic review. Pharmacol Res 209:107430. https:\/\/doi.org\/10.1016\/j.phrs.2024.107430","journal-title":"Pharmacol Res"},{"key":"10333_CR47","doi-asserted-by":"publisher","first-page":"e12775","DOI":"10.1111\/eos.12775","volume":"129","author":"W Buranaphatthana","year":"2021","unstructured":"Buranaphatthana W, Wu S, Makeudom A et al (2021) Involvement of the a disintegrin and metalloproteinase 9 in oral cancer cell invasion. Eur J Oral Sci 129:e12775. https:\/\/doi.org\/10.1111\/eos.12775","journal-title":"Eur J Oral Sci"},{"key":"10333_CR48","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1016\/j.biochi.2013.06.003","volume":"95","author":"X Guo","year":"2013","unstructured":"Guo X, Ma C, Du Q et al (2013) Two peptides, TsAP-1 and TsAP-2, from the venom of the Brazilian yellow scorpion, Tityus serrulatus: evaluation of their antimicrobial and anticancer activities. Biochimie 95:1784\u20131794. https:\/\/doi.org\/10.1016\/j.biochi.2013.06.003","journal-title":"Biochimie"},{"key":"10333_CR49","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1016\/S0041-0101(98)00153-6","volume":"36","author":"H Rochat","year":"1998","unstructured":"Rochat H, Kharrat R, Sabatier J et al (1998) Maurotoxin, a four disulfide bridges scorpion toxin acting on K+ channels. Toxicon 36:1609\u20131611. https:\/\/doi.org\/10.1016\/S0041-0101(98)00153-6","journal-title":"Toxicon"},{"key":"10333_CR50","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.canlet.2017.05.010","volume":"402","author":"I Rady","year":"2017","unstructured":"Rady I, Siddiqui IA, Rady M, Mukhtar H (2017) Melittin, a major peptide component of bee venom, and its conjugates in cancer therapy. Cancer Lett 402:16\u201331. https:\/\/doi.org\/10.1016\/j.canlet.2017.05.010","journal-title":"Cancer Lett"},{"key":"10333_CR51","doi-asserted-by":"publisher","first-page":"112163","DOI":"10.1016\/j.intimp.2024.112163","volume":"134","author":"M Easwaran","year":"2024","unstructured":"Easwaran M, Abdelrahman F, Madasamy S, Venkidasamy B (2024) Phage-delivered melittin for oral squamous cell Carcinoma: a potential therapeutic agent. Int Immunopharmacol 134:112163. https:\/\/doi.org\/10.1016\/j.intimp.2024.112163","journal-title":"Int Immunopharmacol"},{"key":"10333_CR52","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.toxicon.2010.04.019","volume":"56","author":"AM Chudzinski-Tavassi","year":"2010","unstructured":"Chudzinski-Tavassi AM, De-S\u00e1-J\u00fanior PL, Simons SM et al (2010) A new tick Kunitz type inhibitor, Amblyomin-X, induces tumor cell death by modulating genes related to the cell cycle and targeting the ubiquitin-proteasome system. Toxicon 56:1145\u20131154. https:\/\/doi.org\/10.1016\/j.toxicon.2010.04.019","journal-title":"Toxicon"},{"key":"10333_CR53","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1080\/19336918.2018.1516982","volume":"14","author":"MCB Schmidt","year":"2020","unstructured":"Schmidt MCB, Morais KLP, de Almeida MES et al (2020) Amblyomin-X, a recombinant Kunitz-type inhibitor, regulates cell adhesion and migration of human tumor cells. Cell Adh Migr 14:129\u2013138. https:\/\/doi.org\/10.1080\/19336918.2018.1516982","journal-title":"Cell Adh Migr"},{"key":"10333_CR54","doi-asserted-by":"publisher","first-page":"3756","DOI":"10.1038\/s41598-017-03998-x","volume":"7","author":"R Bergmann","year":"2017","unstructured":"Bergmann R, Kubeil M, Zarschler K et al (2017) Distribution and kinetics of the Kv1.3-blocking peptide HsTX1[R14A] in experimental rats. Sci Rep 7:3756. https:\/\/doi.org\/10.1038\/s41598-017-03998-x","journal-title":"Sci Rep"},{"key":"10333_CR55","first-page":"233","volume":"3","author":"C Rap\u00f4so","year":"2017","unstructured":"Rap\u00f4so C (2017) Scorpion and spider venoms in cancer treatment: state of the art, challenges, and perspectives. J Clin Transl Res 3:233\u2013249","journal-title":"J Clin Transl Res"},{"key":"10333_CR56","doi-asserted-by":"publisher","first-page":"10156","DOI":"10.3390\/ijms221810156","volume":"22","author":"P Wadhwani","year":"2021","unstructured":"Wadhwani P, Sekaran S, Strandberg E et al (2021) Membrane interactions of latarcins: antimicrobial peptides from spider venom. Int J Mol Sci 22:10156. https:\/\/doi.org\/10.3390\/ijms221810156","journal-title":"Int J Mol Sci"},{"key":"10333_CR57","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/bip.22748","volume":"106","author":"PG Ojeda","year":"2016","unstructured":"Ojeda PG, Wang CK, Craik DJ (2016) Chlorotoxin: structure, activity, and potential uses in cancer therapy. Pept Sci 106:25\u201336. https:\/\/doi.org\/10.1002\/bip.22748","journal-title":"Pept Sci"},{"key":"10333_CR58","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.3390\/pharmaceutics14122613","volume":"14","author":"A Shrestha","year":"2022","unstructured":"Shrestha A, Lahooti B, Mikelis CM, Mattheolabakis G (2022) Chlorotoxin and lung cancer: a targeting perspective for drug delivery. Pharmaceutics 14:2613. https:\/\/doi.org\/10.3390\/pharmaceutics14122613","journal-title":"Pharmaceutics"},{"key":"10333_CR59","doi-asserted-by":"publisher","first-page":"1203247","DOI":"10.3389\/fphar.2023.1203247","volume":"14","author":"S Mlayah-Bellalouna","year":"2023","unstructured":"Mlayah-Bellalouna S, Aissaoui-Zid D, Chantome A et al (2023) Insights into the mechanisms governing P01 scorpion toxin effect against U87 glioblastoma cells oncogenesis. Front Pharmacol 14:1203247. https:\/\/doi.org\/10.3389\/fphar.2023.1203247","journal-title":"Front Pharmacol"},{"key":"10333_CR60","doi-asserted-by":"publisher","first-page":"84","DOI":"10.52547\/ibj.3863","volume":"27","author":"M Baradaran","year":"2023","unstructured":"Baradaran M, Pashmforoosh N (2023) Peptides with diverse functions from scorpion venom: a great opportunity for the treatment of a wide variety of diseases. Iran Biomed J 27:84\u201399. https:\/\/doi.org\/10.52547\/ibj.3863","journal-title":"Iran Biomed J"},{"key":"10333_CR61","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2017.7613","author":"B Jin","year":"2017","unstructured":"Jin B, Dong X, Xu X, Zhang F (2017) Development and in\u00ef\u00bf\u00bdvitro evaluation of mucoadhesive patches of methotrexate for targeted delivery in oral cancer. Oncol Lett. https:\/\/doi.org\/10.3892\/ol.2017.7613","journal-title":"Oncol Lett"},{"key":"10333_CR62","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1007\/s13346-022-01224-4","volume":"13","author":"L Habib","year":"2023","unstructured":"Habib L, Alyan M, Ghantous Y et al (2023) A mucoadhesive patch loaded with freeze-dried liposomes for the local treatment of oral tumors. Drug Deliv Transl Res 13:1228\u20131245. https:\/\/doi.org\/10.1007\/s13346-022-01224-4","journal-title":"Drug Deliv Transl Res"},{"key":"10333_CR63","doi-asserted-by":"publisher","first-page":"204","DOI":"10.3390\/pharmaceutics17020204","volume":"17","author":"\u00c1EF Alves","year":"2025","unstructured":"Alves \u00c1EF, Barros ABC, Silva LCF et al (2025) Emerging trends in snake venom-loaded nanobiosystems for advanced medical applications: a comprehensive overview. Pharmaceutics 17:204. https:\/\/doi.org\/10.3390\/pharmaceutics17020204","journal-title":"Pharmaceutics"},{"key":"10333_CR64","doi-asserted-by":"publisher","first-page":"371","DOI":"10.3390\/toxins17080371","volume":"17","author":"E Kim","year":"2025","unstructured":"Kim E, Hwang DH, Mohan Prakash RL et al (2025) Animal venom in modern medicine: a review of therapeutic applications. Toxins (Basel) 17:371. https:\/\/doi.org\/10.3390\/toxins17080371","journal-title":"Toxins (Basel)"},{"key":"10333_CR65","doi-asserted-by":"publisher","DOI":"10.7324\/JAPS.2025.220739","author":"D Ramesh","year":"2025","unstructured":"Ramesh D, Bakkannavar SM, Kumar G, Bhat VR (2025) Exploring snake venom-derived molecules for cancer treatment: challenges and opportunities. J Appl Pharm Sci. https:\/\/doi.org\/10.7324\/JAPS.2025.220739","journal-title":"J Appl Pharm Sci"},{"key":"10333_CR66","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2017.7613","author":"B Jin","year":"2017","unstructured":"Jin B, Dong X, Xu X, Zhang F (2017) Development and in vitro evaluation of mucoadhesive patches of methotrexate for targeted delivery in oral cancer. Oncol Lett. https:\/\/doi.org\/10.3892\/ol.2017.7613","journal-title":"Oncol Lett"},{"key":"10333_CR67","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41392-024-02107-5","volume":"10","author":"W Xiao","year":"2025","unstructured":"Xiao W, Jiang W, Chen Z et al (2025) Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines. Signal Transduct Target Ther 10:74. https:\/\/doi.org\/10.1038\/s41392-024-02107-5","journal-title":"Signal Transduct Target Ther"},{"key":"10333_CR68","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s13205-025-04472-6","volume":"15","author":"V Upadhyay","year":"2025","unstructured":"Upadhyay V, Das S, Nehru A et al (2025) Advancing oral squamous cell carcinoma research: the evolving role of patient-derived cell lines, xenografts, and organoid models. 3 Biotech 15:295. https:\/\/doi.org\/10.1007\/s13205-025-04472-6","journal-title":"3 Biotech"},{"key":"10333_CR69","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s41199-020-00056-4","volume":"5","author":"I Tinhofer","year":"2020","unstructured":"Tinhofer I, Braunholz D, Klinghammer K (2020) Preclinical models of head and neck squamous cell carcinoma for a basic understanding of cancer biology and its translation into efficient therapies. Cancers Head Neck 5:9. https:\/\/doi.org\/10.1186\/s41199-020-00056-4","journal-title":"Cancers Head Neck"},{"key":"10333_CR70","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1080\/14789450.2017.1377613","volume":"14","author":"SD Robinson","year":"2017","unstructured":"Robinson SD, Undheim EAB, Ueberheide B, King GF (2017) Venom peptides as therapeutics: advances, challenges and the future of venom-peptide discovery. Expert Rev Proteom 14:931\u2013939. https:\/\/doi.org\/10.1080\/14789450.2017.1377613","journal-title":"Expert Rev Proteom"},{"key":"10333_CR71","doi-asserted-by":"publisher","first-page":"112","DOI":"10.7150\/ijms.35133","volume":"17","author":"S Lepore","year":"2020","unstructured":"Lepore S, Lettini G, Condelli V et al (2020) Comparative gene expression profiling of tobacco-associated HPV-positive versus negative oral squamous carcinoma cell lines. Int J Med Sci 17:112\u2013124. https:\/\/doi.org\/10.7150\/ijms.35133","journal-title":"Int J Med Sci"},{"key":"10333_CR72","doi-asserted-by":"publisher","first-page":"4291","DOI":"10.1158\/1078-0432.CCR-16-0592","volume":"22","author":"Y Yuan","year":"2016","unstructured":"Yuan Y, Hess KR, Hilsenbeck SG, Gilbert MR (2016) Bayesian optimal interval design: a simple and well-performing design for phase I oncology trials. Clin Cancer Res 22:4291\u20134301. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0592","journal-title":"Clin Cancer Res"},{"key":"10333_CR73","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1177\/0022034517735293","volume":"29","author":"RA Burne","year":"2018","unstructured":"Burne RA (2018) Getting to know the known unknowns: heterogeneity in the oral microbiome. Adv Dent Res 29:66\u201370. https:\/\/doi.org\/10.1177\/0022034517735293","journal-title":"Adv Dent Res"},{"key":"10333_CR74","doi-asserted-by":"publisher","first-page":"1629683","DOI":"10.3389\/fcell.2025.1629683","volume":"13","author":"Y Zhao","year":"2025","unstructured":"Zhao Y, Yang J, Jiang Y, Wu J (2025) Integrative multi-omics analysis and experimental validation identify molecular subtypes, prognostic signature, and CA9 as a therapeutic target in oral squamous cell carcinoma. Front Cell Dev Biol 13:1629683. https:\/\/doi.org\/10.3389\/fcell.2025.1629683","journal-title":"Front Cell Dev Biol"},{"key":"10333_CR75","doi-asserted-by":"publisher","first-page":"3845","DOI":"10.3390\/cancers13153845","volume":"13","author":"C McCarthy","year":"2021","unstructured":"McCarthy C, Fedele S, Ottensmeier C, Shaw RJ (2021) Early-phase interventional trials in oral cancer prevention. Cancers (Basel) 13:3845. https:\/\/doi.org\/10.3390\/cancers13153845","journal-title":"Cancers (Basel)"},{"key":"10333_CR76","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.conctc.2018.08.010","volume":"12","author":"AS Ruppert","year":"2018","unstructured":"Ruppert AS, Shoben AB (2018) Overall success rate of a safe and efficacious drug: results using six phase 1 designs, each followed by standard phase 2 and 3 designs. Contemp Clin Trials Commun 12:40\u201350. https:\/\/doi.org\/10.1016\/j.conctc.2018.08.010","journal-title":"Contemp Clin Trials Commun"},{"key":"10333_CR77","doi-asserted-by":"publisher","first-page":"1608401","DOI":"10.3389\/fimmu.2025.1608401","volume":"16","author":"M Puig","year":"2025","unstructured":"Puig M, Shubow S (2025) Immunogenicity of therapeutic peptide products: bridging the gaps regarding the role of product-related risk factors. Front Immunol 16:1608401. https:\/\/doi.org\/10.3389\/fimmu.2025.1608401","journal-title":"Front Immunol"},{"key":"10333_CR78","unstructured":"Study Details, NCT (2026) 04733027 | First-in-human phase I to evaluate PEP-010 as single agent and in combination with paclitaxel or with gemcitabine (CleverPeptide) | ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT04733027. Accessed 12 Mar 2026"},{"key":"10333_CR79","doi-asserted-by":"publisher","first-page":"100071","DOI":"10.1016\/j.medidd.2020.100071","volume":"9","author":"MW Pennington","year":"2021","unstructured":"Pennington MW, Zell B, Bai CJ (2021) Commercial manufacturing of current good manufacturing practice peptides spanning the gamut from neoantigen to commercial large-scale products. Med Drug Discov 9:100071. https:\/\/doi.org\/10.1016\/j.medidd.2020.100071","journal-title":"Med Drug Discov"},{"key":"10333_CR80","unstructured":"Peptide Synthesis & Modification | Aurigene Pharmaceutical Services. https:\/\/www.aurigeneservices.com\/peptide-synthesis-modification. Accessed 12 Mar 2026"},{"key":"10333_CR81","unstructured":"Ensuring Quality & Scale in GMP Peptide & Oligonucleotide API Manufacturing - PharmiWeb.com. https:\/\/www.pharmiweb.com\/article\/ensuring-quality-scale-in-gmp-peptide-oligonucleotide-api-manufacturing. Accessed 13 Mar 2026"},{"key":"10333_CR82","unstructured":"How CDMOs Can Help With Scaling Up Synthetic Peptides https:\/\/www.neulandlabs.com\/en\/insights\/stories\/milligrams-kilograms-scaling-synthetic-peptides. Accessed 13 Mar 2026"}],"container-title":["The Protein Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10930-026-10333-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10930-026-10333-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10930-026-10333-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T09:40:07Z","timestamp":1780134007000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10930-026-10333-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":82,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["10333"],"URL":"https:\/\/doi.org\/10.1007\/s10930-026-10333-9","relation":{},"ISSN":["1875-8355"],"issn-type":[{"value":"1875-8355","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"5 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}